logo
Plus   Neg
Share
Email

Amgen Drug Shrinks 54% Of Lung Cancer Tumors In Study

Amgen (AMGN) announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. Thirteen of the evaluable patients received the target dose of 960 mg once daily, of which seven (54%) achieved a partial response at one or more timepoints and six (46%) achieved stable disease, for a disease control rate of 100%.

AMG 510 is a first-in-class investigational oral therapy that is designed to selectively and irreversibly target the KRASG12C protein.

The company noted that the additional follow-up in a larger group of patients with non-small cell lung cancer (NSCLC) continued to show anti-tumor activity with no dose-limiting toxicities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dunkin' Brands Group said it is rolling out the Beyond Sausage Sandwich to more than 9,000 restaurants nationwide, starting November 6. The sandwich features a plant-based sausage patty from alternative meat maker Beyond Meat. Beyond Meat's breakfast sausage patty is made with plant-based protein and a mix of spices crafted specifically for Dunkin'. Boeing said it understands and regrets the concern caused by the publications of instant messages involving a former test pilot that he "unknowingly" lied to regulators about a flight-control system on the Boeing 737 Max aircraft. The aircraft maker said it especially regrets the difficulties that the release of the messages presented for the U.S. Federal Aviation Administration or FAA. Boeing said Sunday that it had informed the Federal Aviation Administration and international regulators on multiple occasions about the expanded role of the flight-control software in 737 MAX, which was linked to two fatal crashes that killed 346 people.
Follow RTT
>